Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients Journal Article


Authors: Fu, T.; Liu, Y.; Li, K.; Wan, W.; Pappou, E. P.; Iacobuzio-Donahue, C. A.; Kerner, Z.; Baylin, S. B.; Wolfgang, C. L.; Ahuja, N.
Article Title: Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
Abstract: We previously developed a novel tumor subtype classification model for duodenal adenocarcinomas based on a combination of the CpG island methylator phenotype (CIMP) and MLH1 methylation status. Here, we tested the prognostic value of this model in stage II colorectal cancer (CRC) patients. Tumors were assigned to CIMP+/ MLH1-unmethylated (MLH1-U), CIMP+/MLH1-methylated (MLH1-M), CIMP-/MLH1-U, or CIMP-/MLH1-M groups. Age, tumor location, lymphovascular invasion, and mucin production differed among the four patient subgroups, and CIMP+/MLH1-U tumors were more likely to have lymphovascular invasion and mucin production. Kaplan-Meier analyses revealed differences in both disease-free survival (DFS) and overall survival (OS) among the four groups. In a multivariate analysis, CIMP/MLH1 methylation status was predictive of both DFS and OS, and DFS and OS were shortest in CIMP+/ MLH1-U stage II CRC patients. These results suggest that tumor subtype classification based on the combination of CIMP and MLH1 methylation status is informative in stage II CRC patients, and that CIMP+/MLH1-U tumors exhibit aggressive features and are associated with poor clinical outcomes.
Keywords: methylation; colorectal cancer; mlh1; prognosis; cpg island methylator phenotype
Journal Title: Oncotarget
Volume: 7
Issue: 52
ISSN: 1949-2553
Publisher: Impact Journals  
Date Published: 2016-12-27
Start Page: 86480
End Page: 86489
Language: English
PROVIDER: scopus
PUBMED: 27880934
DOI: 10.18632/oncotarget.13441
PMCID: PMC5349928
DOI/URL:
Notes: Article -- Export Date: 2 February 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors